Search results
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 2 months agoThe mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While...
Is NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value?
Simply Wall St. via Yahoo Finance· 3 months agoKey Insights NovoCure's estimated fair value is US$12.01 based on 2 Stage Free Cash Flow to Equity...
Should You Investigate NovoCure Limited (NASDAQ:NVCR) At US$87.50?
Simply Wall St. via Yahoo Finance· 1 year agoWhile NovoCure Limited (NASDAQ:NVCR) might not be the most widely known stock at the moment, it...
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoNovoCure (NVCR) delivered earnings and revenue surprises of -64.29% and 4.39%, respectively, for the...
Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails
Investor's Business Daily· 9 months agoNovocure said Monday its electrical-based cancer treatment failed to make a difference for ovarian...
Why Novocure Was a Healthy Stock Today
Motley Fool· 10 months agoWhat happened Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In...
Why NovoCure Stock Is Falling Today
Motley Fool· 1 year agoShares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results...
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
Zacks via Yahoo Finance· 1 year agoNovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely...
Why Novocure Stock Tumbled by Nearly 16% Today
Motley Fool· 10 months agoWhat happened Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure's (NASDAQ: NVCR) shares on...
